Parmax Pharma Adjusts Evaluation Score Amidst Strong Sales Growth and Financial Challenges

Parmax Pharma, a microcap company in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation score. This revision reflects a shift in technical trends, moving from a mildly bullish stance to a more neutral position.
Key financial metrics indicate that while Parmax Pharma has reported positive results for the last three consecutive quarters, it faces challenges in long-term growth. The company's net sales have shown a significant increase in the latest six months, reaching Rs 11.11 crore, which represents a growth rate of 98.75%. However, the overall financial health is tempered by a negative book value and a weak long-term fundamental strength, highlighted by a concerning EBIT to interest ratio of 0.66.

In terms of stock performance, Parmax Pharma has generated a return of 26.54% over the past year, outperforming the broader market, which recorded a return of 3.25%. Despite this, the company has experienced a decline in its stock price recently, with the current price at Rs 38.00, down from a previous close of Rs 38.70.

For more insights on Parmax Pharma's financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.